Female sex is associated with lower incidence and improved clinical outcomes for many cancer types, including melanoma and pancreatic ductal adenocarcinoma (PDAC). Although the mechanisms responsible for this sex difference are still emerging, we recently showed that signaling through the G protein-coupled estrogen receptor (GPER) likely contributes to improved clinical outcomes in women with melanoma. Here we used newly developed murine syngeneic tumor models to test whether GPER signaling inhibits KRas-driven PDAC. Activation of GPER with the specific, small molecule agonist G-1 inhibited PDAC proliferation, depleted c-Myc and programmed death ligand 1 (PD-L1), induced cell cycle block, and increased tumor cell immunogenicity. Systemically delivered G-1 significantly lengthened survival, and increased the efficacy of immune therapy in PDAC bearing mice, such that up to 60% of mice completely cleared their tumors. We detected GPER protein in a majority of human PDAC tumors.
Introduction
For many cancers, incidence and age-adjusted mortality rates are lower in females than in males, suggesting that biological differences between the sexes influence tumor initiation, progression, and response to modern therapeutics (1) (2) (3) . Understanding the mechanisms responsible for these differences may lead to identification of new therapeutic targets for cancer, including malignancies that are not classically considered sex hormone responsive. Recently, we demonstrated that nonclassical estrogen signaling through the G protein-coupled estrogen receptor (GPER) drives melanocyte differentiation and inhibits melanoma (4, 5) . In mice with therapy-resistant syngeneic melanoma, systemic administration of a specific small molecule GPER agonist, G-1 (6) , induced differentiation in tumor cells that inhibited proliferation and rendered tumors more immunogenic. Combination therapy with G-1 and α-PD-1 immune-checkpoint blockade demonstrated combinatorial anti-tumor activity, with a high percentage of complete responses (50%) that were associated with long-lasting tumor immunity (4) . GPER is expressed in many tissues (7) and signaling downstream of GPER is mediated by ubiquitous cellular proteins that mediate cAMP signaling. Therefore, we hypothesized that selective GPER activation would inhibit other cancers in addition to melanoma, and similarly potentiate the anti-tumor activity of α-PD-1 and other immunotherapies.
To test this idea, we turned to pancreatic ductal adenocarcinoma (PDAC), a highly aggressive cancer that is poorly responsive to current therapy, and a major cause of cancer death in the United States (8) . As with many cancers, women have lower PDAC incidence and more favorable outcomes than men, suggesting that estrogen may suppress PDAC (1, 2, 9) . Consistent with this, use of estradiol containing oral contraceptives, and history of multiple pregnancies (which necessarily correlates with high estrogen exposure) are both associated with decreased PDAC risk (10) (11) (12) . Further supporting the idea that PDAC is influenced by estrogen are human clinical trials showing that tamoxifen, which is a GPER agonist, extends survival in PDAC patients (13, 14) . These data, coupled with lack of clear evidence that nuclear estrogen receptors are expressed and functional in PDAC (15) , led us to consider the possibility that estrogen may influence PDAC through GPER.
Li and colleagues recently generated a library of clonal PDAC tumor cell lines from a genetic engineered mouse model of PDAC, KPCY ('KPCY' mice, KRas LSL-G12D/+ ; Trp53 L/+ or Trp53 LSL-R172H/+ ; Pdx1-Cre; Rosa-YFP), that faithfully recapitulates the molecular, histological, and clinical features of the human disease (3, 16, 17) . In syngeneic, immunocompetent BL/6 mice, the degree of immune infiltration varies with each cell line. This variability reflects the natural heterogeneity in immune infiltrates observed in human PDAC. Here we used these new models to test whether GPER activation affects PDAC tumor growth, and/or improves response to immune checkpoint blockade.
Results and Discussion
To test whether PDAC responds to GPER signaling, we used three of the genetically defined murine PDAC tumor lines that together represent the heterogeneity in immune infiltration and response to immunotherapy: 6419c5 tumors attract minimal CD8+ T cell infiltration and respond poorly to combination therapy with cytotoxic and immune activating agents, 2838c3 tumors attract robust CD8+ T cell infiltration and are highly responsive to therapy, and 6499c4 tumors which are associated with robust CD8+ T-cell infiltration, but only modest responses to therapy (3).
GPER is expressed in all 3 PDAC tumor lines at levels similar to YUMM1.7 melanoma ( Figure   1A ), which we previously showed is highly responsive to GPER signaling (4) . To test whether the effects of GPER activation in PDAC paralleled those in melanoma, we treated the PDAC tumor cell lines with the specific GPER agonist G-1, and observed similar dose-dependent decreases in p-RB, c-Myc, and PD-L1. These changes were associated with decreased proliferation and a Tumor response to anti-PD-1 was different in each tumor line, but was significantly potentiated by G-1 in agents completely cleared tumors in 60% of animals with no evidence of disease at day 100, suggesting a combinatorial benefit. 6419c5 responded to G-1 but was completely resistant to αPD-1 monotherapy.
However, G1+ αPD-1 combination therapy extended survival beyond G-1 monotherapy, again suggesting combinatorial benefit. In contrast, combination therapy did not provide any additional benefit over G-1 monotherapy in 6499c4 tumors, which were only minimally responsive to αPD-1 alone.
In an effort to understand the mechanistic basis for the heterogeneous responses to the G-1:αPD-1 combination regimen, we next tested whether PD-L1 is expressed in each tumor. Using in situ hybridization for PD-L1 in naïve tumors, we detected high levels of PD-L1 expression in 2838c3 and 6419c5, and complete absence of PD-L1 in 6499c4 ( Figure 2E ), suggesting that the combinatorial survival-promoting effect of G-1 and αPD-1 depends on whether the tumor cells express PD-L1.
We next questioned whether GPER was expressed in spontaneous human PDAC. Using a tissue microarray representing several stages of PDAC, immunohistochemical staining for GPER demonstrated both peripheral membrane and punctate cytoplasmic staining, alone or in combination in tumor cells.
There was a wide range of staining intensity across different clinical stages ( Figure 3A-B) . Overall, GPER was detected in 61% of the PDAC cases tested, suggesting that GPER may be a widely expressed, and pharmacologically accessible therapeutic target in human PDAC.
Together with our previous study on melanoma, this work raises the possibility that GPER agonists may have therapeutic utility against a wide array of GPER-expressing cancer types, and critically, may extend the utility of modern immune therapeutics to tumors, such as PDAC, that have thus far been resistant to immune therapy (18) . These data further suggest the importance of G proteincoupled receptor signaling in cancer, that activation of GPER is tumor suppressive in cancers that are not classically hormone responsive, and that GPER activity may underlie biological differences between the sexes that influence cancer progression and response to modern therapies. 
Methods
Cell culture and cell lines 2838c3, 6419c5, 6499c4 murine PDAC cells were derived in the laboratory of Ben Stanger (University of Pennsylvania) and cultured in DMEM (Mediatech, Manassas, VA, USA) with 5% FBS (Invitrogen, Carlsbad, CA, USA) and 1% antibiotic-antimycotic (Invitrogen). Tumor cells wewre regularly tested using MycoAlert Mycoplasma Detection Kit from Lonza (Allendale, NJ, USA). G-1 (10008933) was purchased from Cayman Chemical (Ann Arbor, MI, USA). Cells were trypsinized using 0.05% Trypsin with EDTA (Invitrogen) for 5 minutes to detach from the plate.
Mice
All mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA). Five to seven week old female C57BL/6J mice were allowed to acclimatize for one week prior to being used for experiments. These studies were preformed without inclusion/exclusion criteria or blinding, but included randomization. Based on a twofold-anticipated effect, we performed experiments with at least 5 biological replicates. All procedures were performed in accordance with International Animal Care and Use Committee (IACUC)-approved protocols at the University of Pennsylvania.
Subcutaneous tumors and treatments
Subcutaneous tumors were initiated by injecting tumor cells in 50% Matrigel (Corning, Bedford, MA, USA) into the subcutaneous space on the left and right flanks of mice. 2 x 10 5 of murine PDAC cells were used for each tumor. In vivo G-1 treatments were performed by first dissolving G-1, synthesized as described previously (5), in 100% ethanol at a concentration of 1mg/ml. The desired amount of G-1 was then mixed with an appropriate volume of sesame oil, and the ethanol was evaporated off using a Savant Speed Vac (Thermo Fisher Scientific, Waltham, MA, USA), leaving the desired amount of G-1 dissolved in 50µL of sesame oil per injection at a 10mg/kg dose. Vehicle injections were prepared in an identical manner using 100% ethanol. Vehicle and G-1 injections were delivered through subcutaneous injection as indicated in each experimental timeline. Isotype control antibody (Clone: 2A3, BioXcell, West Lebanon, NH, USA) and αPD-1 antibody (Clone: RMP1-14, BioXcell) were diluted in sterile PBS and delivered through intraperitoneal injections at a dose of 10mg/kg.
Survival Analysis
As subcutaneous tumors grew in mice, perpendicular tumor diameters were measured using calipers. Volume was calculated using the formula L × W^2 × 0.52, where L is the longest dimension and W is the perpendicular dimension. Animals were euthanized when tumors exceeded a protocol-specified size of 15 mm in the longest dimension. Secondary endpoints include severe ulceration, death, and any other condition that falls within the IACUC guidelines for Rodent Tumor and Cancer Models at the University of Pennsylvania.
Western Blot Analysis
Adherent cells were washed once with DPBS, and lysed with 8M urea containing 50mM NaCl and 50mM Tris-HCl, pH 8.3, 10mM dithiothreitol, 50mM iodoacetamide. Lysates were quantified (Bradford assay), normalized, reduced, and resolved by SDS gel electrophoresis on 4-15% Tris/Glycine gels (Bio-Rad, Hercules, CA, USA). Resolved protein was transferred to PVDF membranes (Millipore, Billerica, MA, USA) using a Semi-Dry Transfer Cell (Bio-Rad), blocked in 5% BSA in TBS-T and probed with primary antibodies recognizing β-Actin (Cell Signaling Technology, #3700, 1:4000, Danvers, MA, USA), c-Myc (Cell Signaling Technology, #13987, 1:1000), GPER (Sigma, HPA027052, 1:500), HLA-ABC (Biolegend, w6/32,1:500, San Diego, CA, USA), mouse PD-L1 (R&D systems, AF1019, 1:500, Minneapolis, MN, USA), p-RB (Cell Signaling Technology, #8516, 1:1000), and RB (Cell Signaling Technology, #9313, 1:1000). After incubation with the appropriate secondary antibody, proteins were detected using either Luminata Crescendo Western HRP Substrate (Millipore) or ECL Western Blotting Analysis System (GE Healthcare, Bensalem, PA). All western blots were repeated at least 3 times.
Immunohistochemistry and Quantification FFPE tissue microarrays were purchased from Biomax (9461e, Derwood, MD, USA) and were stained GPER (Novus Biologics, NLS1183, Littleton, CO, USA) as previously described with some modifications (4). Briefly, slides have been deparaffinized and rehydrated in extend time than standard immunohistochemistry protocol ( in three xylenes 7 min each time, 3 times 100% alcohol, 2 time 95% alcohol, ones 70% and 50% alcohol and finished with distill water ). The antigen retrieval was done by immersing the slides in Tris-EDTA pH 8.0 and microwave for 14 minutes at power 9 then cool down to room temperature on the bench, washed three times in wash buffer and blocked sequentially the endogenous peroxidase and non-specific protein binding. The volume and the dilution/concentration (500 ul per slide at the dilution 1:70) of the primary antibody was calculate considering the total area of tissue and incubate overnight at 40C . Following multiple washes secondary antibody, goat anti-rabbit conjugated to HRP was applied, incubated for 20 minutes at room temperature, then washed out and signal was amplified with substrate-DAB chromogen buffer. The tissues were counterstain with hematoxylin, dehydrated, cover-slipped and analyzed. A board-certified pathologist performed scoring of the stained tissue microarray, and scoring index was determined by scoring the percentage of positive cells on a scale of 0 to 3 as well as the intensity of GPER staining on a scale of 0 to 3, these scores were multiplied to generate the scoring index value.
Cell cycle analysis
Tumor cells were cultured in 10% FBS in DMEM following standard cell culture protocol. Hoechst 33342 (ThermoFisher Scientific, #H1399) was added directly to the cell culture medium with the final concentration of 10 ug/mL 1 hour before sample collection. Cells were incubated with Hoechst 33342 at 37C for 1 hour. Then, cells were prepared to single cell suspension using trypsin and washed with PBS twice. Cells were resuspended in flow buffer (1% FBS in PBS) for flow analysis in a BD LSR II flow cytometry machine. Flow results were analyzed using the FlowJo software to assess the percentage of cells in G1 phase and S-G2-M phase.
Cell viability analysis
Tumor cells were cultured in 10% FBS in DMEM following standard cell culture protocol. Cells were prepared to single cell suspension using trypsin and washed with PBS twice. Cells were resuspended in flow buffer (1% FBS in PBS) with DAPI (ThermoFisher Scientific, #D21490) incubation for flow analysis in a BD LSR II flow cytometry machine. Flow results were analyzed using the FlowJo software to assess the percentage of cells with negative staining of DAPI.
RNA-seq
RNA was extracted using RNeasy kit (Qiagen catalog no. 74014) following the manufacturer's instructions. All RNA-seq libraries were prepared using the NEBNext Poly(A) mRNA Magnetic Isolation Module followed by NEBNext Ultra Directional RNA Library Prep Kit for Illumina (both from NEB). Library quality was analyzed using Agilent BioAnalyzer 2100 (Agilent) and libraries were quantified using NEB Library Quantification Kits (NEB). Libraries were then sequenced using a NextSeq500 platform (75bp, single-end reads) (Illumina). All RNA-seq was aligned using RNA STAR under default settings to Homo sapiens UCSC hg19 (RefSeq & Gencode gene annotations). FPKM generation and differential expression analysis was performed using DESeq2. DESeq2 output was analyzed by comparing differentially expressed genes with p<0.05 and HALLMARK gene set enrichment analysis was performed using MSigDB database (19) .
RNA in situ hybridization analysis
Tumor cells were subcutaneously implanted into C57BL/6 mice for tumor growth. Tumors were collected 3 weeks after implantation, fixed with Zinc Formalin Fixative (Polysciences, #21516), and embedded in paraffin. Tumor sample paraffin sections were used for RNA in situ hybridization analysis using the RNAscope 2.5 HD Assay -BROWN (Advanced Cell Diagnosis) with probe targeting CD274 (PD-L1) (420501). The RNA in situ hybridization analysis was performed following standard procedures from the kit manual and published protocol (20) (RNAscope: a novel in situ RNA analysis platform for formalinfixed, paraffin-embedded tissues).
